Furthermore, genetic alterations in the PI3K signaling pathway are commonly observed in HNSCC, and pan-PI3K inhibitor such as buparlisib with paclitaxel improved efficacy in R/M HNSCC patients compared with paclitaxel alone, suggesting that PI3K inhibition plays an important anti-cancer role. Here, PIK3CA is linked to cancer.